{
  "model": "chatgpt-gpt-5.1-codex-mini",
  "taskId": "tumor-vaccine-ici",
  "runIndex": 1,
  "result": {
    "text": "- [x] `output/study_overview.json`\n- [x] `output/quantitative_findings.json`\n- [x] `output/claim_audit.json`\n- [x] `output/public_summary.json`",
    "thoughts": "**Verifying summary compliance**",
    "steps": [
      {
        "step": 1,
        "modelVersion": "chatgpt-gpt-5.1-codex-mini",
        "thoughts": "**Inspecting task details**",
        "toolCalls": [
          {
            "toolName": "list_directory",
            "input": {
              "dir_path": ".",
              "ignore": [],
              "file_filtering_options": null
            },
            "output": "input/\noutput/\nschemas/\nTASK.md",
            "callId": "call_XVwMx0GCCRyXzGPRvUr3ha0A"
          }
        ],
        "usage": {
          "promptTokens": 658,
          "cachedTokens": 0,
          "responseTokens": 39,
          "thinkingTokens": 0,
          "totalTokens": 697
        },
        "costUsd": 0.00024249999999999999
      },
      {
        "step": 2,
        "modelVersion": "chatgpt-gpt-5.1-codex-mini",
        "thoughts": "**Preparing to follow instructions**",
        "toolCalls": [
          {
            "toolName": "read_file",
            "input": {
              "file_path": "TASK.md",
              "offset": 0,
              "limit": 400
            },
            "output": "L1: # Agent Task\nL2: \nL3: Task id: tumor-vaccine-ici\nL4: Task title: mRNA tumor sensitization for checkpoint blockade\nL5: Reference paper: SARS-CoV-2 mRNA vaccines sensitize tumours to immune checkpoint blockade\nL6: Reference URL: https://www.nature.com/articles/s41586-025-09006-8\nL7: \nL8: ## Objective\nL9: Read the report and produce all required JSON outputs that satisfy their schemas.\nL10: \nL11: ## Inputs On Disk\nL12: - Report: `input/report.md`\nL13: - Schemas: in `schemas/`\nL14: \nL15: ## Required Outputs\nL16: - `output/study_overview.json` (schema: `schemas/study_overview.schema.json`)\nL17: - `output/quantitative_findings.json` (schema: `schemas/quantitative_findings.schema.json`)\nL18: - `output/claim_audit.json` (schema: `schemas/claim_audit.schema.json`)\nL19: - `output/public_summary.json` (schema: `schemas/public_summary.schema.json`)\nL20: \nL21: ## Constraints\nL22: - Do not invent source facts; derive calculations only from values in the report.\nL23: - Use line refs as `L<number>` where required.\nL24: - Where quotes are required, copy exact report snippets.\nL25: - For calculation outputs, line_refs must include every report line used for equations, constants, and numeric substitutions.\nL26: - Keep attribution exact: do not restate combined-arm effects as single-intervention effects.\nL27: - For retrospective/observational human data, use association language unless causality is explicitly established in the report.\nL28: - If `output/public_summary.json` is required, include at least two control/null/conditional findings from the report in the summary/caution fields.\nL29: - Use relative paths only.\nL30: - Never use absolute paths.\nL31: - Never use `..` in paths.\nL32: - Write valid JSON only.\nL33: \nL34: ## Completion\nL35: Respond with a checklist of written output files.\nL36: After the checklist, stop. Do not call more tools.",
            "callId": "call_HggPS1lbpqdEof0wo6Zm1WD2"
          }
        ],
        "usage": {
          "promptTokens": 703,
          "cachedTokens": 0,
          "responseTokens": 41,
          "thinkingTokens": 0,
          "totalTokens": 744
        },
        "costUsd": 0.00025775
      },
      {
        "step": 3,
        "modelVersion": "chatgpt-gpt-5.1-codex-mini",
        "thoughts": "**Reading report and schema**",
        "toolCalls": [
          {
            "toolName": "read_file",
            "input": {
              "file_path": "input/report.md",
              "offset": 0,
              "limit": 400
            },
            "output": "L1: # Structured Paper Report: Tumor Sensitization by mRNA Vaccination\nL2: \nL3: ## Citation\nL4: - Title: SARS-CoV-2 mRNA vaccines sensitize tumours to immune checkpoint blockade\nL5: - Journal: Nature\nL6: - Year: 2025\nL7: - DOI: 10.1038/s41586-025-09006-8\nL8: - Source URL: https://www.nature.com/articles/s41586-025-09006-8\nL9: \nL10: ## One-Paragraph Context\nL11: Immune checkpoint inhibitors (ICIs) can produce durable responses in some cancers, but many tumors remain non-responsive due to weak antigen presentation or poor immune priming. The paper investigates whether intratumoral delivery of an mRNA vaccine can create an interferon-rich inflammatory state that improves sensitivity to anti-PD-L1 therapy.\nL12: \nL13: ## Study Design Snapshot\nL14: - Preclinical arm: multiple murine tumor models with intratumoral mRNA vaccine and anti-PD-L1 combinations.\nL15: - Translational arm: a retrospective cohort of metastatic patients receiving ICI treatment, compared by prior SARS-CoV-2 mRNA vaccination status.\nL16: - Mechanistic probes: immunopeptidomics, transcriptomics, and perturbation controls (including IFNAR1 blockade and non-mRNA particle controls).\nL17: \nL18: ## Cohorts and Scenarios\nL19: 1. Mouse efficacy cohort (combination therapy): 78 tumor-bearing mice pooled across repeat experiments.\nL20: 2. Mouse control cohort (vaccine only, ICI only, and vehicle): 84 tumor-bearing mice pooled across matched controls.\nL21: 3. Human retrospective metastatic cohort: 130 patients total.\nL22: 4. Human vaccinated subgroup: 43 patients.\nL23: 5. Human unvaccinated subgroup: 87 patients.\nL24: \nL25: ## Quantitative Findings\nL26: | Metric | Vaccine/Combination Arm | Comparator | Interpretation |\nL27: |---|---:|---:|---|\nL28: | Fraction of tumor proteins represented in immunopeptidome | 62.3% | 37.3% | Broader antigen display after intratumoral mRNA vaccination |\nL29: | Fraction of proteins represented in MHC-I peptidome | 40.6% | 20.6% | Strong expansion of MHC-I-presented landscape |\nL30: | Retrospective human survival comparison p-value | p=0.01 | N/A | Vaccinated subgroup had improved survival under ICI treatment |\nL31: | Type I interferon response score (normalized units) | 3.1 | 1.0 | Marked induction after mRNA vaccination in tumors |\nL32: | PD-L1 expression fold-change in tumor tissue | 2.4x | 1.0x | Checkpoint axis became more targetable |\nL33: | Intratumoral CD8+ T-cell density fold-change | 1.8x | 1.0x | Increased immune infiltration with combination therapy |\nL34: \nL35: ## Controls and Null/Conditional Results\nL36: - Vaccine-only treatment did not produce durable tumor control in non-immunogenic models.\nL37: - ICI-only treatment had limited activity in low-immunogenic baseline settings.\nL38: - Lipid particle controls lacking mRNA did not reproduce the sensitization effect.\nL39: - Blocking type I interferon signaling with anti-IFNAR1 eliminated the observed sensitization benefit.\nL40: \nL41: ## Mechanistic Chain Proposed by Authors\nL42: 1. Intratumoral mRNA vaccination triggers local innate sensing and type I interferon signaling.\nL43: 2. Interferon-associated antigen processing and presentation pathways increase.\nL44: 3. A broader peptide repertoire appears on MHC-I, improving tumor visibility to T cells.\nL45: 4. PD-L1 pathway activity also increases, creating a rationale for combining with checkpoint blockade.\nL46: 5. Combined intervention improves tumor control in mice and aligns with better outcomes in the retrospective human cohort.\nL47: \nL48: ## Caveats and Threats to Validity\nL49: - The human analysis is retrospective and non-randomized; residual confounding is likely.\nL50: - Vaccination timing relative to ICI initiation varied across patients.\nL51: - Tumor-type mix and treatment-history heterogeneity limit direct causal interpretation.\nL52: - Mouse model effects may not map one-to-one to all human tumors.\nL53: - Some mechanistic readouts were strongest in specific model systems rather than uniformly across all tested settings.\nL54: \nL55: ## Practical Takeaway\nL56: The study supports a biologically coherent hypothesis that intratumoral mRNA vaccination can prime tumors for stronger ICI responses, but prospective randomized studies are required before clinical protocol changes are justified.",
            "callId": "call_TtAeStflfvS5EN0YxzfKrZu0"
          }
        ],
        "usage": {
          "promptTokens": 1229,
          "cachedTokens": 0,
          "responseTokens": 54,
          "thinkingTokens": 0,
          "totalTokens": 1283
        },
        "costUsd": 0.00041524999999999993
      },
      {
        "step": 4,
        "modelVersion": "chatgpt-gpt-5.1-codex-mini",
        "thoughts": "**Requesting schema details**",
        "toolCalls": [
          {
            "toolName": "list_directory",
            "input": {
              "dir_path": "schemas",
              "ignore": [],
              "file_filtering_options": null
            },
            "output": "claim_audit.schema.json\npublic_summary.schema.json\nquantitative_findings.schema.json\nstudy_overview.schema.json",
            "callId": "call_Z0ATAwx2v4esdsDtE2fVo65e"
          }
        ],
        "usage": {
          "promptTokens": 2330,
          "cachedTokens": 0,
          "responseTokens": 39,
          "thinkingTokens": 0,
          "totalTokens": 2369
        },
        "costUsd": 0.0006605000000000001
      },
      {
        "step": 5,
        "modelVersion": "chatgpt-gpt-5.1-codex-mini",
        "toolCalls": [
          {
            "toolName": "read_file",
            "input": {
              "file_path": "schemas/study_overview.schema.json",
              "offset": 0,
              "limit": 400
            },
            "output": "L1: {\nL2:   \"$schema\": \"http://json-schema.org/draft-07/schema#\",\nL3:   \"title\": \"schemas-study_overview\",\nL4:   \"type\": \"object\",\nL5:   \"properties\": {\nL6:     \"paper\": {\nL7:       \"type\": \"object\",\nL8:       \"properties\": {\nL9:         \"title\": {\nL10:           \"type\": \"string\",\nL11:           \"minLength\": 10\nL12:         },\nL13:         \"doi\": {\nL14:           \"type\": \"string\",\nL15:           \"pattern\": \"^10\\\\.\"\nL16:         },\nL17:         \"publication_year\": {\nL18:           \"type\": \"integer\",\nL19:           \"minimum\": 1900,\nL20:           \"maximum\": 2100\nL21:         },\nL22:         \"domain\": {\nL23:           \"type\": \"string\",\nL24:           \"enum\": [\nL25:             \"oncology-immunology\",\nL26:             \"exoplanet-atmospheres\",\nL27:             \"climate-science\",\nL28:             \"neuroscience\",\nL29:             \"other\"\nL30:           ]\nL31:         },\nL32:         \"study_type\": {\nL33:           \"type\": \"string\",\nL34:           \"enum\": [\nL35:             \"preclinical+retrospective\",\nL36:             \"observational-astronomy\",\nL37:             \"randomized-trial\",\nL38:             \"simulation\",\nL39:             \"mixed\"\nL40:           ]\nL41:         }\nL42:       },\nL43:       \"required\": [\nL44:         \"title\",\nL45:         \"doi\",\nL46:         \"publication_year\",\nL47:         \"domain\",\nL48:         \"study_type\"\nL49:       ],\nL50:       \"additionalProperties\": false\nL51:     },\nL52:     \"core_question\": {\nL53:       \"type\": \"string\",\nL54:       \"minLength\": 20\nL55:     },\nL56:     \"datasets_or_cohorts\": {\nL57:       \"type\": \"array\",\nL58:       \"items\": {\nL59:         \"type\": \"object\",\nL60:         \"properties\": {\nL61:           \"id\": {\nL62:             \"type\": \"string\",\nL63:             \"pattern\": \"^[a-z0-9-]+$\"\nL64:           },\nL65:           \"label\": {\nL66:             \"type\": \"string\",\nL67:             \"minLength\": 3\nL68:           },\nL69:           \"sample_size_or_observations\": {\nL70:             \"type\": \"string\",\nL71:             \"minLength\": 1\nL72:           },\nL73:           \"description\": {\nL74:             \"type\": \"string\",\nL75:             \"minLength\": 20\nL76:           }\nL77:         },\nL78:         \"required\": [\nL79:           \"id\",\nL80:           \"label\",\nL81:           \"sample_size_or_observations\",\nL82:           \"description\"\nL83:         ],\nL84:         \"additionalProperties\": false\nL85:       },\nL86:       \"minItems\": 2,\nL87:       \"maxItems\": 8\nL88:     },\nL89:     \"major_limitations\": {\nL90:       \"type\": \"array\",\nL91:       \"items\": {\nL92:         \"type\": \"string\",\nL93:         \"minLength\": 12\nL94:       },\nL95:       \"minItems\": 3,\nL96:       \"maxItems\": 8\nL97:     }\nL98:   },\nL99:   \"required\": [\nL100:     \"paper\",\nL101:     \"core_question\",\nL102:     \"datasets_or_cohorts\",\nL103:     \"major_limitations\"\nL104:   ],\nL105:   \"additionalProperties\": false\nL106: }",
            "callId": "call_j33dLpR1FrucRE0G5YWdAo8O"
          }
        ],
        "usage": {
          "promptTokens": 2390,
          "cachedTokens": 1152,
          "responseTokens": 33,
          "thinkingTokens": 0,
          "totalTokens": 2423
        },
        "costUsd": 0.00040429999999999996
      },
      {
        "step": 6,
        "modelVersion": "chatgpt-gpt-5.1-codex-mini",
        "toolCalls": [
          {
            "toolName": "read_file",
            "input": {
              "file_path": "schemas/quantitative_findings.schema.json",
              "offset": 0,
              "limit": 400
            },
            "output": "L1: {\nL2:   \"$schema\": \"http://json-schema.org/draft-07/schema#\",\nL3:   \"title\": \"schemas-quantitative_findings\",\nL4:   \"type\": \"object\",\nL5:   \"properties\": {\nL6:     \"findings\": {\nL7:       \"type\": \"array\",\nL8:       \"items\": {\nL9:         \"type\": \"object\",\nL10:         \"properties\": {\nL11:           \"id\": {\nL12:             \"type\": \"string\",\nL13:             \"pattern\": \"^Q[0-9]{2}$\"\nL14:           },\nL15:           \"metric\": {\nL16:             \"type\": \"string\",\nL17:             \"minLength\": 6\nL18:           },\nL19:           \"value\": {\nL20:             \"type\": \"string\",\nL21:             \"minLength\": 1\nL22:           },\nL23:           \"comparator_or_baseline\": {\nL24:             \"type\": \"string\",\nL25:             \"minLength\": 1\nL26:           },\nL27:           \"interpretation\": {\nL28:             \"type\": \"string\",\nL29:             \"minLength\": 12\nL30:           },\nL31:           \"evidence_line_refs\": {\nL32:             \"type\": \"array\",\nL33:             \"items\": {\nL34:               \"type\": \"string\",\nL35:               \"pattern\": \"^L[1-9]\\\\d*$\"\nL36:             },\nL37:             \"minItems\": 1,\nL38:             \"maxItems\": 3\nL39:           }\nL40:         },\nL41:         \"required\": [\nL42:           \"id\",\nL43:           \"metric\",\nL44:           \"value\",\nL45:           \"comparator_or_baseline\",\nL46:           \"interpretation\",\nL47:           \"evidence_line_refs\"\nL48:         ],\nL49:         \"additionalProperties\": false\nL50:       },\nL51:       \"minItems\": 5,\nL52:       \"maxItems\": 14\nL53:     },\nL54:     \"controls_or_null_results\": {\nL55:       \"type\": \"array\",\nL56:       \"items\": {\nL57:         \"type\": \"object\",\nL58:         \"properties\": {\nL59:           \"statement\": {\nL60:             \"type\": \"string\",\nL61:             \"minLength\": 10\nL62:           },\nL63:           \"evidence_line_ref\": {\nL64:             \"$ref\": \"#/definitions/schemas-quantitative_findings/properties/findings/items/properties/evidence_line_refs/items\"\nL65:           }\nL66:         },\nL67:         \"required\": [\nL68:           \"statement\",\nL69:           \"evidence_line_ref\"\nL70:         ],\nL71:         \"additionalProperties\": false\nL72:       },\nL73:       \"minItems\": 2,\nL74:       \"maxItems\": 10\nL75:     }\nL76:   },\nL77:   \"required\": [\nL78:     \"findings\",\nL79:     \"controls_or_null_results\"\nL80:   ],\nL81:   \"additionalProperties\": false\nL82: }",
            "callId": "call_S9EwavDTORgevgWDKW6LAbEJ"
          }
        ],
        "usage": {
          "promptTokens": 3337,
          "cachedTokens": 2304,
          "responseTokens": 34,
          "thinkingTokens": 0,
          "totalTokens": 3371
        },
        "costUsd": 0.0003838499999999999
      },
      {
        "step": 7,
        "modelVersion": "chatgpt-gpt-5.1-codex-mini",
        "toolCalls": [
          {
            "toolName": "read_file",
            "input": {
              "file_path": "schemas/claim_audit.schema.json",
              "offset": 0,
              "limit": 400
            },
            "output": "L1: {\nL2:   \"$schema\": \"http://json-schema.org/draft-07/schema#\",\nL3:   \"title\": \"schemas-claim_audit\",\nL4:   \"type\": \"object\",\nL5:   \"properties\": {\nL6:     \"claims\": {\nL7:       \"type\": \"array\",\nL8:       \"items\": {\nL9:         \"type\": \"object\",\nL10:         \"properties\": {\nL11:           \"claim_id\": {\nL12:             \"type\": \"string\",\nL13:             \"pattern\": \"^C[0-9]{2}$\"\nL14:           },\nL15:           \"claim\": {\nL16:             \"type\": \"string\",\nL17:             \"minLength\": 20\nL18:           },\nL19:           \"strength\": {\nL20:             \"type\": \"string\",\nL21:             \"enum\": [\nL22:               \"strong\",\nL23:               \"moderate\",\nL24:               \"tentative\"\nL25:             ]\nL26:           },\nL27:           \"evidence\": {\nL28:             \"type\": \"array\",\nL29:             \"items\": {\nL30:               \"type\": \"object\",\nL31:               \"properties\": {\nL32:                 \"quote\": {\nL33:                   \"type\": \"string\",\nL34:                   \"minLength\": 10\nL35:                 },\nL36:                 \"line_ref\": {\nL37:                   \"type\": \"string\",\nL38:                   \"pattern\": \"^L[1-9]\\\\d*$\"\nL39:                 }\nL40:               },\nL41:               \"required\": [\nL42:                 \"quote\",\nL43:                 \"line_ref\"\nL44:               ],\nL45:               \"additionalProperties\": false\nL46:             },\nL47:             \"minItems\": 2,\nL48:             \"maxItems\": 3\nL49:           },\nL50:           \"caveat\": {\nL51:             \"type\": \"string\",\nL52:             \"minLength\": 20\nL53:           }\nL54:         },\nL55:         \"required\": [\nL56:           \"claim_id\",\nL57:           \"claim\",\nL58:           \"strength\",\nL59:           \"evidence\",\nL60:           \"caveat\"\nL61:         ],\nL62:         \"additionalProperties\": false\nL63:       },\nL64:       \"minItems\": 4,\nL65:       \"maxItems\": 10\nL66:     }\nL67:   },\nL68:   \"required\": [\nL69:     \"claims\"\nL70:   ],\nL71:   \"additionalProperties\": false\nL72: }",
            "callId": "call_lmhoQGDvFFG5dibhHwanCnMl"
          }
        ],
        "usage": {
          "promptTokens": 4114,
          "cachedTokens": 2304,
          "responseTokens": 33,
          "thinkingTokens": 0,
          "totalTokens": 4147
        },
        "costUsd": 0.0005761
      },
      {
        "step": 8,
        "modelVersion": "chatgpt-gpt-5.1-codex-mini",
        "toolCalls": [
          {
            "toolName": "read_file",
            "input": {
              "file_path": "schemas/public_summary.schema.json",
              "offset": 0,
              "limit": 400
            },
            "output": "L1: {\nL2:   \"$schema\": \"http://json-schema.org/draft-07/schema#\",\nL3:   \"title\": \"schemas-public_summary\",\nL4:   \"type\": \"object\",\nL5:   \"properties\": {\nL6:     \"headline\": {\nL7:       \"type\": \"string\",\nL8:       \"minLength\": 20,\nL9:       \"maxLength\": 120\nL10:     },\nL11:     \"plain_language_summary\": {\nL12:       \"type\": \"string\",\nL13:       \"minLength\": 180,\nL14:       \"maxLength\": 1200\nL15:     },\nL16:     \"what_is_new\": {\nL17:       \"type\": \"array\",\nL18:       \"items\": {\nL19:         \"type\": \"string\",\nL20:         \"minLength\": 20\nL21:       },\nL22:       \"minItems\": 3,\nL23:       \"maxItems\": 3\nL24:     },\nL25:     \"why_caution_is_needed\": {\nL26:       \"type\": \"array\",\nL27:       \"items\": {\nL28:         \"type\": \"string\",\nL29:         \"minLength\": 20\nL30:       },\nL31:       \"minItems\": 3,\nL32:       \"maxItems\": 5\nL33:     },\nL34:     \"glossary\": {\nL35:       \"type\": \"array\",\nL36:       \"items\": {\nL37:         \"type\": \"object\",\nL38:         \"properties\": {\nL39:           \"term\": {\nL40:             \"type\": \"string\",\nL41:             \"minLength\": 2\nL42:           },\nL43:           \"definition\": {\nL44:             \"type\": \"string\",\nL45:             \"minLength\": 20,\nL46:             \"maxLength\": 220\nL47:           }\nL48:         },\nL49:         \"required\": [\nL50:           \"term\",\nL51:           \"definition\"\nL52:         ],\nL53:         \"additionalProperties\": false\nL54:       },\nL55:       \"minItems\": 4,\nL56:       \"maxItems\": 8\nL57:     },\nL58:     \"open_questions\": {\nL59:       \"type\": \"array\",\nL60:       \"items\": {\nL61:         \"type\": \"string\",\nL62:         \"minLength\": 20\nL63:       },\nL64:       \"minItems\": 3,\nL65:       \"maxItems\": 6\nL66:     }\nL67:   },\nL68:   \"required\": [\nL69:     \"headline\",\nL70:     \"plain_language_summary\",\nL71:     \"what_is_new\",\nL72:     \"why_caution_is_needed\",\nL73:     \"glossary\",\nL74:     \"open_questions\"\nL75:   ],\nL76:   \"additionalProperties\": false\nL77: }",
            "callId": "call_STxWA3nuW56u37OEkVU6kg1u"
          }
        ],
        "usage": {
          "promptTokens": 4758,
          "cachedTokens": 4096,
          "responseTokens": 31,
          "thinkingTokens": 0,
          "totalTokens": 4789
        },
        "costUsd": 0.0003299
      },
      {
        "step": 9,
        "modelVersion": "chatgpt-gpt-5.1-codex-mini",
        "thoughts": "**Organizing detailed data extraction plan**\n\nI’m breaking down the report’s content carefully, noting line references for quantitative data, claims with evidence, controls, and limitations to form a comprehensive blueprint. I’m mapping out all required sections—study overview, datasets, claims, public summary, glossary, and open questions—with precise line-level citations to ensure full traceability before moving on to writing the JSON output files.**Detailing dataset and claim structures**\n\nI’m defining dataset entries with clear ids, labels, sample sizes, and descriptions that reference lines from the report, ensuring the minimum required items and character lengths are met. I’m also preparing claim audit details with exact quote strings, evidence line refs, claim strengths, and tailored caveats drawn from different report lines to provide precise attribution and appropriate caution.**Organizing claim caveats and evidence quotes**\n\nI’m carefully assigning exact caution strings from specific lines to each claim to ensure precise attribution, while choosing appropriate direct quote texts for evidence, including line numbers and formatting details like bullets or numbering exactly as in the report. I’m also planning the structure for related files like the public summary with required fields, lengths, and referencing controls and limitations consistently.**Preparing study overview JSON for writing**\n\nI’m carefully assembling the `study_overview.json` content with detailed paper info, a core question, datasets with proper descriptions and sample sizes, and a list of major limitations referencing exact line texts. My focus is on crafting valid JSON with correct formatting to avoid rewrite loops when saving the file.",
        "toolCalls": [
          {
            "toolName": "write_file",
            "input": {
              "file_path": "output/study_overview.json",
              "content": "{\n  \"paper\": {\n    \"title\": \"SARS-CoV-2 mRNA vaccines sensitize tumours to immune checkpoint blockade\",\n    \"doi\": \"10.1038/s41586-025-09006-8\",\n    \"publication_year\": 2025,\n    \"domain\": \"oncology-immunology\",\n    \"study_type\": \"preclinical+retrospective\"\n  },\n  \"core_question\": \"Does intratumoral SARS-CoV-2 mRNA vaccination prime tumors to respond more effectively to anti-PD-L1 checkpoint blockade?\",\n  \"datasets_or_cohorts\": [\n    {\n      \"id\": \"mouse-combo\",\n      \"label\": \"Mouse combination therapy cohort\",\n      \"sample_size_or_observations\": \"78 tumor-bearing mice pooled across repeat experiments\",\n      \"description\": \"Preclinical cohort testing intratumoral mRNA vaccine plus anti-PD-L1 therapy for tumor control in multiple murine models.\"\n    },\n    {\n      \"id\": \"mouse-control\",\n      \"label\": \"Mouse matched control cohorts\",\n      \"sample_size_or_observations\": \"84 tumor-bearing mice across vaccine-only, ICI-only, and vehicle groups\",\n      \"description\": \"Matched control tumors evaluating vaccine-only, ICI-only, and vehicle treatments without combined therapy.\"\n    },\n    {\n      \"id\": \"human-retrospective\",\n      \"label\": \"Retrospective metastatic patient cohort\",\n      \"sample_size_or_observations\": \"130 metastatic patients total\",\n      \"description\": \"Retrospective analysis comparing ICI outcomes by prior SARS-CoV-2 mRNA vaccination status among metastatic patients.\"\n    }\n  ],\n  \"major_limitations\": [\n    \"The human analysis is retrospective, non-randomized, and likely confounded.\",\n    \"Vaccination timing relative to ICI initiation varied across patients.\",\n    \"Tumor-type mix and treatment-history heterogeneity limit direct causal interpretation.\",\n    \"Mouse model effects may not map one-to-one to all human tumors.\"\n  ]\n}\n"
            },
            "output": "Successfully wrote file: output/study_overview.json",
            "callId": "call_LgU1UWzOQApZM9ADcTkQYdI0"
          }
        ],
        "usage": {
          "promptTokens": 5472,
          "cachedTokens": 4736,
          "responseTokens": 508,
          "thinkingTokens": 12032,
          "totalTokens": 18012
        },
        "costUsd": 0.0253824
      },
      {
        "step": 10,
        "modelVersion": "chatgpt-gpt-5.1-codex-mini",
        "toolCalls": [
          {
            "toolName": "write_file",
            "input": {
              "file_path": "output/claim_audit.json",
              "content": "{\n  \"claims\": [\n    {\n      \"claim_id\": \"C01\",\n      \"claim\": \"Intratumoral SARS-CoV-2 mRNA vaccination sensitizes tumors to anti-PD-L1 checkpoint blockade in murine models.\",\n      \"strength\": \"strong\",\n      \"evidence\": [\n        {\n          \"quote\": \"Combined intervention improves tumor control in mice and aligns with better outcomes in the retrospective human cohort.\",\n          \"line_ref\": \"L46\"\n        },\n        {\n          \"quote\": \"Intratumoral mRNA vaccination triggers local innate sensing and type I interferon signaling.\",\n          \"line_ref\": \"L42\"\n        }\n      ],\n      \"caveat\": \"Findings in mouse models may not translate to all human tumors.\"\n    },\n    {\n      \"claim_id\": \"C02\",\n      \"claim\": \"A broader peptide repertoire appears on MHC-I after vaccination, improving tumor visibility to T cells.\",\n      \"strength\": \"moderate\",\n      \"evidence\": [\n        {\n          \"quote\": \"A broader peptide repertoire appears on MHC-I, improving tumor visibility to T cells.\",\n          \"line_ref\": \"L44\"\n        },\n        {\n          \"quote\": \"Fraction of tumor proteins represented in immunopeptidome | 62.3% | 37.3% | Broader antigen display after intratumoral mRNA vaccination\",\n          \"line_ref\": \"L28\"\n        }\n      ],\n      \"caveat\": \"Antigen presentation changes are shown in mice and may vary by tumor type.\"\n    },\n    {\n      \"claim_id\": \"C03\",\n      \"claim\": \"Retrospective human analysis associates prior mRNA vaccination with better survival under ICI treatment.\",\n      \"strength\": \"tentative\",\n      \"evidence\": [\n        {\n          \"quote\": \"Retrospective human survival comparison p-value | p=0.01 | N/A | Vaccinated subgroup had improved survival under ICI treatment\",\n          \"line_ref\": \"L30\"\n        },\n        {\n          \"quote\": \"Retrospective cohort of metastatic patients receiving ICI treatment, compared by prior SARS-CoV-2 mRNA vaccination status.\",\n          \"line_ref\": \"L15\"\n        }\n      ],\n      \"caveat\": \"The analysis is retrospective and likely confounded, limiting causal claims.\"\n    },\n    {\n      \"claim_id\": \"C04\",\n      \"claim\": \"Blocking type I interferon signaling eliminates the sensitization benefit seen with mRNA vaccination.\",\n      \"strength\": \"moderate\",\n      \"evidence\": [\n        {\n          \"quote\": \"Blocking type I interferon signaling with anti-IFNAR1 eliminated the observed sensitization benefit.\",\n          \"line_ref\": \"L39\"\n        },\n        {\n          \"quote\": \"Intratumoral mRNA vaccination triggers local innate sensing and type I interferon signaling.\",\n          \"line_ref\": \"L42\"\n        }\n      ],\n      \"caveat\": \"The mechanistic chain is described in specific models and may differ in other settings.\"\n    }\n  ]\n}\n"
            },
            "output": "Successfully wrote file: output/claim_audit.json",
            "callId": "call_ZEWdVjkYjADqx5EJ4ZlLqDd9"
          }
        ],
        "usage": {
          "promptTokens": 5986,
          "cachedTokens": 0,
          "responseTokens": 775,
          "thinkingTokens": 0,
          "totalTokens": 6761
        },
        "costUsd": 0.0030464999999999997
      },
      {
        "step": 11,
        "modelVersion": "chatgpt-gpt-5.1-codex-mini",
        "thoughts": "**Organizing quantitative and public summary data****Finalizing summary components and plans**",
        "toolCalls": [
          {
            "toolName": "write_file",
            "input": {
              "file_path": "output/quantitative_findings.json",
              "content": "{\n  \"findings\": [\n    {\n      \"id\": \"Q01\",\n      \"metric\": \"Fraction of tumor proteins represented in the immunopeptidome\",\n      \"value\": \"62.3%\",\n      \"comparator_or_baseline\": \"37.3%\",\n      \"interpretation\": \"Broader antigen display after intratumoral mRNA vaccination\",\n      \"evidence_line_refs\": [\n        \"L28\"\n      ]\n    },\n    {\n      \"id\": \"Q02\",\n      \"metric\": \"Fraction of proteins represented in the MHC-I peptidome\",\n      \"value\": \"40.6%\",\n      \"comparator_or_baseline\": \"20.6%\",\n      \"interpretation\": \"Strong expansion of the MHC-I-presented landscape\",\n      \"evidence_line_refs\": [\n        \"L29\"\n      ]\n    },\n    {\n      \"id\": \"Q03\",\n      \"metric\": \"Retrospective human survival comparison p-value\",\n      \"value\": \"p=0.01\",\n      \"comparator_or_baseline\": \"N/A\",\n      \"interpretation\": \"Vaccinated subgroup had improved survival under ICI treatment\",\n      \"evidence_line_refs\": [\n        \"L30\"\n      ]\n    },\n    {\n      \"id\": \"Q04\",\n      \"metric\": \"Type I interferon response score (normalized units)\",\n      \"value\": \"3.1\",\n      \"comparator_or_baseline\": \"1.0\",\n      \"interpretation\": \"Marked induction after mRNA vaccination in tumors\",\n      \"evidence_line_refs\": [\n        \"L31\"\n      ]\n    },\n    {\n      \"id\": \"Q05\",\n      \"metric\": \"PD-L1 expression fold-change in tumor tissue\",\n      \"value\": \"2.4x\",\n      \"comparator_or_baseline\": \"1.0x\",\n      \"interpretation\": \"Checkpoint axis became more targetable\",\n      \"evidence_line_refs\": [\n        \"L32\"\n      ]\n    },\n    {\n      \"id\": \"Q06\",\n      \"metric\": \"Intratumoral CD8+ T-cell density fold-change\",\n      \"value\": \"1.8x\",\n      \"comparator_or_baseline\": \"1.0x\",\n      \"interpretation\": \"Increased immune infiltration with combination therapy\",\n      \"evidence_line_refs\": [\n        \"L33\"\n      ]\n    }\n  ],\n  \"controls_or_null_results\": [\n    {\n      \"statement\": \"Vaccine-only treatment did not produce durable tumor control in non-immunogenic models.\",\n      \"evidence_line_ref\": \"L36\"\n    },\n    {\n      \"statement\": \"ICI-only treatment had limited activity in low-immunogenic baseline settings.\",\n      \"evidence_line_ref\": \"L37\"\n    },\n    {\n      \"statement\": \"Lipid particle controls lacking mRNA did not reproduce the sensitization effect.\",\n      \"evidence_line_ref\": \"L38\"\n    }\n  ]\n}\n"
            },
            "output": "Successfully wrote file: output/quantitative_findings.json",
            "callId": "call_kgj972fALYBg306uPr0ewyRi"
          }
        ],
        "usage": {
          "promptTokens": 6773,
          "cachedTokens": 0,
          "responseTokens": 788,
          "thinkingTokens": 4288,
          "totalTokens": 11849
        },
        "costUsd": 0.01184525
      },
      {
        "step": 12,
        "modelVersion": "chatgpt-gpt-5.1-codex-mini",
        "thoughts": "**Preparing detailed public summary**\n\nI'm piecing together a clear summary that emphasizes at least two control or null findings from the report, especially about vaccine-only durability and interferon blocking effects. I'll include a thorough plain language summary that highlights observational human associations and craft caution and open question sections addressing retrospective study limits and control results. Glossary and what-is-new entries will cover key terms like mRNA vaccination and immune checkpoint blockade, aiming to meet all specified length and content requirements.",
        "toolCalls": [
          {
            "toolName": "write_file",
            "input": {
              "file_path": "output/public_summary.json",
              "content": "{\n  \"headline\": \"Intratumoral mRNA vaccination may boost checkpoint blockade sensitivity in tumors\",\n  \"plain_language_summary\": \"In preclinical mouse models, intratumoral delivery of a SARS-CoV-2 mRNA vaccine triggers type I interferon signaling, broadens the tumor immunopeptidome, and enhances PD-L1 targetability and CD8+ infiltration, aligning with an association between prior vaccination and better survival in a retrospective metastatic patient cohort. Vaccine-only or ICI-only controls showed limited durable benefit, underscoring that the observed tumor sensitization required the combination approach.\",\n  \"what_is_new\": [\n    \"Intratumoral SARS-CoV-2 mRNA vaccination induces local innate sensing and IFN-driven antigen processing, potentially explaining the broadened peptide repertoire on MHC-I.\",\n    \"Broad antigen presentation and increased PD-L1 expression in mouse tumors create a biological rationale for pairing the vaccine with anti-PD-L1 checkpoint blockade.\",\n    \"A retrospective human cohort links prior SARS-CoV-2 mRNA vaccination with improved survival under ICI, consistent with the mouse combination findings.\n\"  ],\n  \"why_caution_is_needed\": [\n    \"The human analysis was retrospective, non-randomized, and likely residual confounding remains, so associations rather than causality are supported.\",\n    \"Vaccine-only treatment did not produce durable tumor control in non-immunogenic models, indicating the benefit depends on the combination regimen.\",\n    \"ICI-only treatment had limited activity in low-immunogenic baselines, so improved outcomes cannot be attributed to ICI alone in these settings.\",\n    \"Mouse model effects may not translate directly to all human tumors due to species and tumor-type differences.\"\n  ],\n  \"glossary\": [\n    {\n      \"term\": \"mRNA vaccine\",\n      \"definition\": \"A vaccine that delivers messenger RNA encoding antigenic proteins to cells, prompting antigen presentation and immune priming against those proteins.\"\n    },\n    {\n      \"term\": \"Immune checkpoint blockade\",\n      \"definition\": \"Therapies such as anti-PD-L1 antibodies that release inhibitory brakes on T cells, enabling stronger anti-tumor responses.\"\n    },\n    {\n      \"term\": \"Type I interferon signaling\",\n      \"definition\": \"A cascade of innate immune signals induced by viral sensing that enhances antigen presentation and antiviral states within tissues.\"\n    },\n    {\n      \"term\": \"Immunopeptidome\",\n      \"definition\": \"The collection of peptides displayed on MHC molecules, which dictate immune recognition of tumor cells.\"\n    }\n  ],\n  \"open_questions\": [\n    \"Can prospective randomized trials confirm that intratumoral mRNA vaccination causally increases ICI response rates across diverse human tumors?\",\n    \"Which tumor types or immune microenvironments derive the greatest benefit from the combination of mRNA vaccination and checkpoint blockade?\",\n    \"What is the optimal timing and sequencing of vaccination relative to ICI initiation to maximize durable responses?\"\n  ]\n}\n"
            },
            "output": "Successfully wrote file: output/public_summary.json",
            "callId": "call_MxIFYadxiqXzLto38Rjc5Exg"
          }
        ],
        "usage": {
          "promptTokens": 7550,
          "cachedTokens": 6656,
          "responseTokens": 710,
          "thinkingTokens": 384,
          "totalTokens": 8644
        },
        "costUsd": 0.0025778999999999997
      },
      {
        "step": 13,
        "modelVersion": "chatgpt-gpt-5.1-codex-mini",
        "text": "- [x] `output/study_overview.json`\n- [x] `output/quantitative_findings.json`\n- [x] `output/claim_audit.json`\n- [x] `output/public_summary.json`",
        "thoughts": "**Verifying summary compliance**",
        "toolCalls": [],
        "usage": {
          "promptTokens": 8263,
          "cachedTokens": 6912,
          "responseTokens": 85,
          "thinkingTokens": 64,
          "totalTokens": 8412
        },
        "costUsd": 0.00080855
      }
    ],
    "totalCostUsd": 0.04693075
  }
}
